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Elevated serum or plasma concentration of immunoreactive tumor necrosis factor (TNF) is
consistently detected in patients with malaria. TNF levels correlate with high parasitemia and
clinical severity but not always with outcome. Since the effects of TNF may be neutralized by
soluble TNF receptors, sera of 30 nonimmune patients with malaria were analyzed before and
during antimalarial therapy. High concentrations of receptors Rl (55 kDa) and R2 (75 kDa)
were detected immunologically in all sera of untreated patients. Levels of immunoreactive TNF
correlated closely with levels of soluble TNF Rl and R2 (r = .75 and .59, respectively). In
contrast, sera lacked cytotoxic activity against target cells in the TNF bioassays. Soluble TNF
receptor levels remained elevated for days after treatment. These results suggest that excessive
release of TNF induced by the asexual stage of malaria parasites is controlled by a subsequent
shedding of soluble TNF receptors that may bind and deactivate biologically functional TNF.
Regulatory mechanisms are needed to control the poten-
tially hazardous biologic effects of cytokines, such as tumor
necrosis factor (TNF). As recently reviewed [I], malaria is
associated with increased production and release of TNF,
and malaria symptoms are similar to those observed after
administration ofTNF. To exert either beneficial or harmful
effects in the host, TNF must interact with receptors on tar-
get cells. Two immunologically distinct cellular TNF recep-
tors (R I and R2) have recently been identified and charac-
terized by molecular cloning techniques [2]. RI is 55 kDa
and R2 is 75 kDa, and each mediates distinct cellular re-
sponses [3]. As well as being differentially expressed on TNF
target cells [4], these two receptors are also found in biologic
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fluids [5], where they may buffer excessive TNF or act as a
transport protein from which biologically active TNF is
slowly released [2].
High serum concentrations of immunoreactive TNF are
associated with disease severity in falciparum malaria [I].
TNF is probably released in response to schizont rupture [6].
Several studies have found close correlations between para-
sitemia and immunoreactive TNF [7-9]. However, TNF
serum levels are low in some cases of comatose or fatal ma-
laria but extremely high in some survivors who experience
only minor complications. Supportive treatment of severe
malaria with neutralizing anti-TNF antibodies has been pro-
posed, but this strategy may not take into account regulatory
mechanisms involving soluble TNF receptors. Therefore, we
have analyzed the levels of R I and R2 in 30 nonimmune
patients with malaria.
Materials and Methods
Patients. Thirty patients with malaria were treated in the
clinical department of the Tropical Institut in Hamburg be-
tween January and April 1990. Except for 3 African immi-
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grants, who had lived in Germany ~2 years, all patients were
Europeans (ages, 16-65 years; 22 male, 8 female). All but I had
contracted malaria while traveling in Africa, most for the first
time. Malaria was diagnosed in thick and thin blood films.
Twenty-seven patients suffered from Plasmodium falciparum
and 3 from Plasmodium vivax infections. All received adequate
antimalarial treatment [8, 10]. Nine patients with P. falciparum
malaria had one or more complications, which caused them to
be classified as having severe malaria [8]. Of these 9 patients, 6
had impaired cerebral function (disorientation, drowsiness, and
unconsciousness), and 3 had abnormal global clotting tests
(prothrombin time activity <50% and partial thromboplastin
time >45 s). Other complications included renal dysfunction (3
patients: serum creatinine> 176 Jtmol/L or 2 mg/dL) and respi-
ratory insufficiency (I patient: P02 <70 mm Hg). One patient
died 24 h after admission and start of treatment.
Blood samples. Samples were obtained in accordance with
the hospital's routine blood sampling protocol [10]. Samples
were obtained on day 0 (before treatment) and on days l, 2, 4,
and 7 of therapy for parasite, differential blood cell, and platelet
counts and for coagulation parameters, neopterin, and blood
chemistry (including creatinine, liver transaminases, and serum
electrolytes). Parasites were counted in 2000 erythrocytes for
calculation of parasitemia. Serum samples were prepared imme-
diately by centrifugation (2000 g) for 10 min at room tempera-
ture, and suitable aliquots were stored at -80°C until analysis.
Samples from 5 healthy volunteers were included as controls.
Analysis of TNF and soluble TNF receptors in sera. TNF
serum concentrations were determined in duplicate by a sand-
wich immunoradiometric assay (IRMA) (EIA; Medgenix,
Fleurus, Belgium). Bioactivity ofTNF was assayed colorimetri-
cally as cytotoxicity to L929 cells and to mouse fibrosarcoma
cells WEHI 164 [II]. Human recombinant TNF (specific activ-
ity, 6 X 107 units/rug as determined by the supplier in a bioassay
with murine tumor cells) and a polyclonal rabbit antibody to
human TNF (neutralizing capacity, 2 X 105 units/rnl.) were
provided by G. R. Adolf (Ernst-Boehringer-Institut, Vienna).
Serial sample dilutions were tested in duplicate. A serum dilu-
tion causing 50% cell lysis was defined as containing I unit/ml,
TNF. Calculation was done by probit analysis.
The soluble TNF receptor assayswere designed to detect only
functionally active receptor fragments by using enzyme-labeled
recombinant human TNF as the revealing agent. Simultaneous
presence of < I0 ng/mL TNF in plasma did not influence the
results, indicating that free as well as reversibly occupied soluble
TNF receptor molecules were detected. Briefly, the purified
monoclonal mouse antibodies, clone utr-4 against TNF RI (55
kDa) and clone htr-20 against TNF R2 (75 kDa), were coated
on microtiter plates (Immuno Plate, Maxisorp F 96; Nunc, Ros-
kilde, Denmark). For determination of soluble TNF receptors,
the samples and standards (0-5 ng/mL R I and R2) were incu-
bated in the coated microtiter plates (immunologic binding). At
the same time, recombinant TNF-horseradish peroxidase con-
jugate (biologic binding) was added to the test solution. After
washing, peroxidase bound to the microtiter plate was measured
enzymatically. The detection limit of the two ELIBAs (Hoff-
man-La Roche) is --100 pg/mL for both soluble TNF RI
and R2.
Statistical analysis. Levels of significance were determined
by nonparametric tests (Wilcoxon-Mann-Whitney). Spearman
correlation coefficients between different parameters were cal-
culated.
Results
TNF concentration and activity. Elevated immunoreac-
tive TNF serum levels (>20 pg/mL) were found in all sera of
malarial patients before treatment (table 1). TNF levels
correlated with parasitemia (r = .51), serum neopterin (r =
.59), a second line marker of macrophage activation, and
with low platelet counts (r = -.59). Patients with cerebral
symptoms or coagulation abnormalities, which by definition
identified them as having complicated malaria, had higher
serum TNF concentrations than those with uncomplicated
falciparum malaria or vivax malaria (P = .028). In addition,
the serum levels of neopterin, enabled the two groups to be
distinguished (P = .0009). Sera were examined for TNF
bioactivity by L929 and WEHI 164 bioassays. Using human
Table 1. Cell counts or concentrations (median and range) in untreated malaria patients.
Uncomplicated Complicated
Normal falciparum (n = 18) falciparum malaria All patients
Parameters range or vivax malaria (n = 3) P (n = 9) (n = 30)
Parasitized erythrocytes/JtL None 18 (4.5-133.0) .0272 182 (3-758) 30 (3-758)
Platelet count/sl, 150-450 89 (38-297) .0051 29 (9-137) 78 (9-297)
Neopterin (nmol/L) <10* 69 (28-140) .0009 161 (75-750) 81 (28-750)
TNF IRMA (pg/mL) <15* 83 (24-186) .0283 189 (59-518) 87 (24-518)
TNF bioassays (pg/mL) <40* <40 NA <40 <40
Soluble TNF receptors (ng/mL)
RI (55 kDa) 1.2-2.0* 4.6 (1.3-13.2) .0007 18.5 (6.1-43.8) 5.8 (1.3-43.8)
R2 (75 kDa) 0.2-1.4* 9.5 (2.4-19.9) .0007 47.2 (12.0-118.3) 11.5 (2.4-118.3)
TNF:TNF receptor ratio" NA 3.0 (1.4-6.1) NA 5.5 (2.0-1l.l) 5.1 (1.4-11.1)
NOTE. IRMA. immunoradiometric assay; NA. not applicable.
* Healthy controls (n = 5).
t TNF IRMA divided by sum of both soluble TNF receptors (p55 and p75).
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recombinant TNF as a standard, the lower detection limit of
the WEHI 164 assay was 40 pg/mL TNF. Bioactive TNF
could not be detected in sera in any ofthe cytotoxicity assays
(table 1).
TNF receptorproteins. The serum concentrations ofsolu-
ble TNF receptors (R 1 and R2) were increased in patients
with malaria compared to controls (table I). The serum lev-
els of both R 1 and R2 correlated with those of TNF deter-
mined by IRMA (r = .75 and .59, respectively). In addition,
soluble TNF receptor levels were associated with disease se-
verity (P = .0007 for both receptors). The highest R 1and R2
levels were observed in 6 patients with cerebral malaria. In I
patient who died 24 h after admission and start oftreatment,
the pretreatment serum IRMA TNF level was 232 pg/ml.,
and no bioactive TNF was detectable by bioassay. R I and
R2 concentrations were increased (24.0 and 65.1 ng/ml.,
respectively) in this patient. The TNF to soluble TNF recep-
tor ratio might provide an estimate of the relative excess of
TNF. The median ratio ofpatients with complicated malaria
was about half that of patients with uncomplicated malaria
(3.0 vs. 5.5; table 1). This may indicate that in response to
severe infection the available soluble TNF receptors are re-
duced.
TNF IRMA and receptor levels during chemotherapy.
Specific antimalarial treatment led to a rapid clearance of
parasitemia, defervescence, and normalization of laboratory
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Figure 1. Serum concentrations ofTNF and soluble TNF (sTNF) receptors in patients with falciparum malaria before, during, and after
chemotherapy. Follow-up data on 3 patients with cerebral malaria (pt. 1-3) and 3 with uncomplicated malaria (pt. 4-6) are shown. IRMA,
immunoradiometric assay.
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parameters within days in 29 patients. Samples from 6 pa-
tients, 3 of whom presented with cerebral symptoms, were
studied during follow-up. In complicated falciparum ma-
laria, R 1 and R2 decreased rapidly during the first 2 days as
did the TNF levels (figure l). In cases of uncomplicated ma-
laria, the pretreatment soluble TNF receptor levels were in-
creased compared to those ofcontrols; however, day 2 levels
remained in the same range. Increased concentrations of the
receptors were detected in sera of all 6 patients 7 days after
the start of treatment, regardless of the initial quantity (me-
dian concentrations for R 1 and R2: 2.9 and 6. 1 ng/ml., re-
spectively). This suggests that receptor turnover remains en-
hanced and that TNF-responsive systems may still be
activated.
Discussion
Elevated serum concentrations of TNF R 1 and R2 were
observed in all 30 patients under study; exceptionally high
levels were found in patients with complicated malaria. Also,
concentrations ofR 1and R2 correlated closely with those of
immunoreactive TNF (r = .75 and .59). This might reflect
the fact that most immunologic assays for TNF detect this
cytokine both in its native form and in complex with recep-
tor proteins [12]. Serum levels of TNF R2 in our malarial
patients exceeded those of R 1 in all but 1 patient.
We reanalyzed TNF serum levels by bioassay using two
TNF-sensitive cell lines. In both assays the cytotoxic activity
serves as the main parameter ofTNF bioactivity. None ofthe
samples, including those with the highest TNF serum levels
and those from the patient who died of malaria, were found
to affect the growth ofthe TNF-sensitive cell lines. An expla-
nation may be that any TNF in the samples may have been
neutralized in vitro by an excess of soluble TNF receptors.
Furthermore, biologically functional TNF may be deacti-
vated in vivo as well, although there are several arguments
against this explanation. Sera from malarial patients (immu-
noreactive TNF-detectable) up-regulate synthesis of tissue
factor by endothelial cells from human umbilical veins in a
dose-dependent manner that corresponds to the concentra-
tion of immunoreactive TNF [10]. In addition, elevated
serum interleukin-6 (IL-6) concentrations have been found,
and the bioactivity could be neutralized in patient's sera us-
ing oligoclonal anti-IL-6 antibodies [8]. We have also found
the TNF-inducible intercellular adhesion molecule 1 to be
up-regulated on circulating monocytes of these patients (un-
published data). Thus, the failure to detect bioactive TNF in
sera containing high concentrations of soluble TNF recep-
tors does not allow us to conclude that the increased concen-
trations of IRMA TNF are irrelevant in vivo.
As recently demonstrated [3], the binding ofTNF to TNF
R 1 or R2 seems to initiate distinct signaling pathways and
therefore mediate different cellular responses. Binding to R 1
leads to cytotoxicity and antiviral activity at high TNF con-
centrations, whereas binding to R2 stimulates proliferation
of thymocytes and T lymphocytes at low TNF concentra-
tions. However, the specific function of each receptor is still
under debate [2]. The observed close correlation ofimmuno-
reactive TNF and soluble TNF receptors may mean there is
another second line marker of immune activation, similar to
neopterin or IL-6, which was elevated in most of the samples
from these patients (data not shown; R 1 and R2 correlation
coefficients, r = 044 and AI, respectively).
Interestingly, the relative excess of soluble TNF receptors
becomes smaller in patients with complicated malaria as
roughly calculated from our data. Thus, the neutralizing ef-
fects of soluble TNF receptors may help to prevent the po-
tentially harmful effectsofTNF in an uncomplicated clinical
situation but may fail in cases ofexcessive TNF production.
TNF-mediated diseases can be overcome not only by
TNF-specific monoclonal antibodies [1] or inhibitors of
TNF synthesis [13] but also by recombinant TNF-receptor
proteins as has recently been shown in animal models [14].
Therefore, it may be possible to analyze the therapeutic ef-
fect of these molecules in a suitable animal model, such as
Plasmodium vinckei malaria [15]. If administration of these
receptor proteins prevents complications, studies on human
malaria might compare the efficacy of different ways to neu-
tralize or reduce excessive amounts of circulating TNF.
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